Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Nach D-Wave – die nächste Quanten-Aktie geht durch die Decke (Der Aktionaer) +++ D-WAVE Aktie +4,14%

ANI PHARMA Aktie

 >ANI PHARMA Aktienkurs 
50.5 EUR    (Tradegate)
Ask: 51 EUR / 59 Stück
Bid: 50 EUR / 61 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
ANI PHARMA Aktie über LYNX handeln
>ANI PHARMA Performance
1 Woche: -4,6%
1 Monat: -14,5%
3 Monate: -6,8%
6 Monate: -5,9%
1 Jahr: -10,0%
laufendes Jahr: -1,4%
>ANI PHARMA Aktie
Name:  ANI PHARMACEUT. DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00182C1036 / A1W15D
Symbol/ Ticker:  BSFA (Frankfurt) / ANIP (NASDAQ)
Kürzel:  FRA:BSFA, ETR:BSFA, BSFA:GR, NASDAQ:ANIP
Index:  -
Webseite:  https://anipharmaceutical..
Marktkapitalisierung:  1160 Mio. EUR
Umsatz:  599.59 Mio. EUR
EBITDA:  80.5 Mio. EUR
Gewinn je Aktie:  -0.943 EUR
Schulden:  560.24 Mio. EUR
Liquide Mittel:  138.04 Mio. EUR
Umsatz-/ Gewinnwachstum:  43.4% / -13.9%
KGV/ KGV lG:  51.36 / 9.29
KUV/ KBV/ PEG:  1.67 / 2.98 / -
Gewinnm./ Eigenkapitalr.:  -3.12% / -4.57%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  4 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 373.383 USD.
Suchwörter:  ANI PHARMA, ANI PHARMACEUTICALS
Letzte Datenerhebung:  23.05.25
>ANI PHARMA Eigentümer
Aktien: 21.65 Mio. St.
f.h. Aktien: 16.43 Mio. St.
Insider Eigner: 10.98%
Instit. Eigner: 100.42%
>ANI PHARMA Peer Group

 
22.05.25 - 12:54
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares (GlobeNewswire EN)
 
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares...
17.05.25 - 01:01
Insiderhandel: SVP, GENERICS verkauft Aktien von ANI Pharmaceuticals im Wert von 52922 USD (Insiderkauf)
 
Gutwerg, Ori - Vorstand - Tag der Transaktion: 2025-05-15...
16.05.25 - 04:01
Insiderhandel: HEAD OF RARE DISEASE verkauft Aktien von ANI Pharmaceuticals im Wert von 241800 USD (Insiderkauf)
 
Mutz, Christopher - Vorstand - Tag der Transaktion: 2025-05-14...
14.05.25 - 03:01
Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 24880 USD (Insiderkauf)
 
Cook, Meredith - Vorstand - Tag der Transaktion: 2025-05-13...
13.05.25 - 23:01
Insiderhandel: HEAD OF R&D, COO-NOVITIUM OPS verkauft Aktien von ANI Pharmaceuticals im Wert von 53781 USD (Insiderkauf)
 
Shanmugam, Muthusamy - Vorstand - Tag der Transaktion: 2025-05-09...
13.05.25 - 00:33
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ (GlobeNewswire EN)
 
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:...
09.05.25 - 18:45
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact (Benzinga)
 
ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth. read more...
09.05.25 - 17:51
ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 16:00
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates (Zacks)
 
ANI (ANIP) delivered earnings and revenue surprises of 24.09% and 9.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
09.05.25 - 13:24
ANI Pharmaceuticals, Inc. Q1 Profit Decreases, But Beats Estimates (AFX)
 
WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) reported earnings for first quarter that decreased from the same period last year but beat the Street estimates.The company's bottom line ca......
09.05.25 - 12:57
ANI Pharmaceuticals Non-GAAP EPS of $1.70 beats by $0.32, revenue of $197.12M beats by $16.43M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 12:54
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance (GlobeNewswire EN)
 
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025....
08.05.25 - 19:00
ANI Pharmaceuticals Q1 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 19:45
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
 
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products....
02.05.25 - 17:30
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week′s Release (Zacks)
 
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
24.04.25 - 16:00
Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI (Zacks)
 
Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI are part of the Zacks Screen of the Week article....
23.04.25 - 16:00
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue (Zacks)
 
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain....
15.04.25 - 03:01
Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 27584 USD (Insiderkauf)
 
Cook, Meredith - Vorstand - Tag der Transaktion: 2025-04-14...
12.04.25 - 00:33
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) (Benzinga)
 
Latest Ratings for ANIP DateFirmActionFromTo Nov 2021Raymond JamesMaintainsOutperform Nov 2021Truist SecuritiesInitiates Coverage OnBuy May 2021Raymond JamesMaintainsOutperform View More Analyst Ratings for ANIP View the Latest Analyst Ratings read more...
09.04.25 - 12:54
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET (GlobeNewswire EN)
 
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Hamsterrad schaut von innen aus wie eine Karriereleiter. - Roland Düringer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!